Effects of mibefradil, a novel calcium channel blocking agent with T- type activity, in acute experimental myocardial ischemia: Maintenance of ventricular fibrillation threshold without inotropic compromise

Journal of the American College of Cardiology

Volumn 32, Issue 1, 1998, Pages 268-274

  Muller, Cecilia A ^a,c   Opie, Lionel H ^a   McCarthy, Joy ^a   Hofmann, Dirk ^a   Pineda, Carlos A ^b   Peisach, Max ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL ACCELERATOR CENTRE   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; VERAPAMIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART ARRHYTHMIA; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART VENTRICLES; INFUSIONS, INTRAVENOUS; MALE; MIBEFRADIL; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SWINE; TETRAHYDRONAPHTHALENES; VENTRICULAR FIBRILLATION; VERAPAMIL;

EID: 0032127085     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00182-X     Document Type: Article

References (49)

1. Domanski M.J., Zipes D.P., Schron E. Treatment of sudden death. Current understandings from randomized trials and future research directions. Circulation. 95:1997;2694-2699.
2. Murray CJL, Lopez AD, editors. The Global Burden of Disease. Boston (MA): Harvard School of Public Health, 1996:327-95.
3. Clusin W.T., Buchbinder M., Harrison D.C. Calcium overload, "injury" current early ischaemic cardiac arrhythmias - a direct connection. Lancet. 1:1983;272-274.
4. Lubbe W.F., Podzuweit T., Opie L.H. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors . J Am Col Cardiol. 19:1992;1622-1633.
5. Thandroyen F.T., Morris A.C., Hagler H.K., et al. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res. 69:1991;810-819.
6. Billman G.E., Hamlin R.L. The effects of mibefradil a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther. 227:1996;1517-1526.
7. Merillat J.C., Lakatta E.G., Hano O., Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res. 67:1990;1115-1123.
8. The effects of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil Infarction Trial-II). Am J Cardiol. 66:1990;779-785.
9. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
10. Thandroyen F.T. Protective action of calcium channel antagonist agents against ventricular fibrillation in isolated perfused rat heart. J Mol Cell Cardiol. 14:1982;21-32.
11. Kaumann A.J., Aramendia P. Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Ther. 164:1968;326-332.
12. Sherman L.G., Liang C.S., Boden W.E., Hood W.B. The effect of verapamil on mechanical performance of acutely ischemic and reperfused myocardium in the conscious dog. Circ Res. 48:1981;224-232.
13. Temesy-Armos P.N., Legenza M., Southworth S.R., Hoffman B.F. Effects of verapamil and lidocaine in a canine model of sudden coronary death. J Am Coll Cardiol. 6:1985;674-681.
14. Muller C.A., Thandroyen F.T., Hamm C.W., et al. Verapamil and tiapamil in prevention of ventricular fibrillation in pigs with coronary artery ligation. Comparative effects on left ventricular function. Circulation. 78:1988;227-232.
15. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 13:1989;754-759.
16. Bühler F.R., Fleckenstein-Grün G., Clozel J.-P., et al. Mibefradil, a new class of calcium antagonists From molecular biology to clinical benefit . J Cardiovasc Pharmacol. 27:1996;S1-S3.
17. Katz A.M. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 28:1996;522-529.
18. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
19. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 73:1993;777-782.
20. 2+ channels in guinea-pig heart cells. J Physiol (Lond). 456:1992;247-265.
21. 2+ channels and pharmacological blockade Potential pathophysiological relevance . Cardiovasc Drugs Ther. 11:1997;723-739.
22. Fermini B., Nathan R.D. Removal of sialic acid alters both T- and L-type calcium currents in cardiac myocytes. Am J Physiol. 260:1991;H735-H743.
23. Clozel J.-P., Osterrieder W., Kleinbloesem C.H., et al. Ro 40-5967 a new nondihydropyridine calcium antagonist . Cardiovasc Drug Rev. 9:1991;4-17.
24. Mulder P., Richard V., Compagnon P., et al. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol. 29:1997;416-421.
25. Rousseau M.F., Hayashida W., van Eyll C., et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 28:1996;972-979.
26. 2+ antagonist Ro 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol. 23:1994;869-876.
27. 2+ antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Naunyn Schmiedebergs Arch Pharmacol. 348:1992;191-196.
28. Katz A.M. Physiology of the Heart. 1977;324 Raven Press, New York.
29. Lubbe W.F., Podzuweit T., Daries P.S., Opie L.H. The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest. 61:1978;1260-1269.
30. Hearse D.J., Opie L.H., Katzeff I.E., et al. Characterization of the 'border zone' in acute regional ischemia in the dog. Am J Cardiol. 40:1977;716-725.
31. Lubbe W.F., Peisach M., Pretorius R., Bruyneel K.J.J., Opie L.H. Distribution of myocardial blood flow before and after coronary artery ligation in the baboon. Relation to early ventricular fibrillation. Cardiovasc Res. 8:1974;478-487.
32. Roberts R., Husain A., Ambos H.D., Oliver G.C., Cox J.R. Jr, Sobel B.E. Relationship between infarct size and ventricular arrhythmias. Br Heart J. 37:1975;1169-1175.
33. Kaplinsky E., Horowitz A., Neufeld H.B. Ventricular reentry and automaticity in myocardial infarction effect of size of injury . Chest. 74:1978;67-71.
34. Wallenstein S., Zucker C.L., Fleiss J.L. Some statistical methods useful in circulation research. Circ Res. 47:1980;1-9.
35. Braun S., van der Wall E.E., Emanuelsson H., Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris a multicenter placebo-controlled study . J Am Col Cardiol. 27:1996;317-322.
36. Shaw R.M., Rudy Y. Ionic mechanisms of propagation in cardiac tissue. Circ Res. 81:1997;727-741.
37. 2+ inward current by Ro 40-5967 and verapamil relation to negative inotropy . Eur J Pharmacol. 196:1991;205-207.
38. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 48:1995;540-549.
39. Janse A.J., Kléber A.G. Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia. Circ Res. 49:1981;1069-1081.
40. Opie L.H., Coetzee W.A., Dennis S.C., Thandroyen F.T. A potential role for calcium ions in early ischemic and reperfusion arrhythmias. Ann NY Acad Sci. 522:1998;464-477.
41. Küng C.F., Tschudi M.R., Noll G., Clozel J.-P., Lüscher T.F. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol. 26:1995;312-318.
42. Bean B.P. Pharmacology of calcium channels in cardiac muscle, vascular muscle and neurons. Am J Hypertens. 4:(Suppl):1991;406S-411S.
43. Kihara Y., Morgan J.P. Intracellular calcium and ventricular fibrillation Studies in the aequorin-loaded isovolumic ferret heart . Circ Res. 68:1991;1378-1389.
44. 2+ transients under action potential clamp in guinea pig ventricular myocytes. Am J Physiol. 261:1991;C393-C397.
45. Opie L.H., Coetzee W.A. Role of calcium ions in reperfusion arrhythmias relevance to pharmacological intervention . Cardiovasc Drugs Ther. 2:1988;623-636.
46. Coetzee W.A., Opie L.H. Effects of components of ischaemia and metabolic inhibition on delayed afterdepolarizations in guinea pig papillary muscle. Circ Res. 61:1987;157-165.
47. Muller C.A., Opie L.H., Peisach M., Pineda C.A. Chronic oral pretreatment with the angiotensin enzyme inhibitor trandolapril decreases ventricular fibrillation in acute ischemia and reperfusion. Eur Heart J. 15:1994;988-996.
48. Muller C.A., Kralios A.C. Synergistic effects of haemodynamic stabilization and beta-blockade on ventricular fibrillation threshold in coronary artery ligated pigs. Cardiovasc Res. 27:1993;274-278.
49. Verrier R.L., Brooks W.W., Lown B. Protective zone and the determination of vulnerability to ventricular fibrillation. Am J Physiol. 234:1978;H592-H596.